On the public citation graph
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
0 signed · 78 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-aopenalex-snapshot
The National Comprehensive Cancer Network
inferredcites →https://doi.org/10.1002/path.4140openalex-snapshot
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
inferredcites →https://doi.org/10.1016/j.bpobgyn.2016.08.006openalex-snapshot
Epidemiology of epithelial ovarian cancer
inferredcites →https://doi.org/10.1016/j.ejca.2016.03.005openalex-snapshot
Homologous recombination deficiency and ovarian cancer
inferredcites →https://doi.org/10.1016/j.gore.2021.100699openalex-snapshot
PARPi after PARPi in epithelial ovarian cancer
inferredcites →https://doi.org/10.1016/j.ygyno.2011.01.020openalex-snapshot
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
inferredcites →https://doi.org/10.1016/j.ygyno.2014.02.039openalex-snapshot
PARP inhibitors in ovarian cancer: Current status and future promise
inferredcites →https://doi.org/10.1016/j.ygyno.2017.03.504openalex-snapshot
A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: An NRG oncology study
inferredcites →https://doi.org/10.1016/j.ygyno.2019.04.022openalex-snapshot
PARPi after PARPi in epithelial ovarian cancer
inferredcites →https://doi.org/10.1016/s0140-6736openalex-snapshot
Correspondence - Tranexamic acid for traumatic brain injury
inferredcites →https://doi.org/10.1016/s0140-6736(14)62223-6openalex-snapshot
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
inferredcites →https://doi.org/10.1016/s0140-6736(17)32440-6openalex-snapshot
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045openalex-snapshot
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.
inferredcites →https://doi.org/10.1016/s1470-2045(14)70228-1openalex-snapshot
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(14)70391-2openalex-snapshot
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
inferredcites →https://doi.org/10.1016/s1470-2045(14)71135-0openalex-snapshot
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30469-2openalex-snapshot
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(18)30566-7openalex-snapshot
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials
inferredcites →https://doi.org/10.1016/s1470-2045(18)30905-7openalex-snapshot
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
inferredcites →https://doi.org/10.1038/nature03443openalex-snapshot
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
inferredcites →https://doi.org/10.1038/nature03445openalex-snapshot
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
inferredcites →https://doi.org/10.1038/nature10760openalex-snapshot
The DNA damage response and cancer therapy
inferredcites →https://doi.org/10.1038/s41467-018-05564-zopenalex-snapshot
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
inferredcites →https://doi.org/10.1053/j.seminoncol.2006.03.012openalex-snapshot
Management of Platinum-Sensitive Recurrent Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa052985openalex-snapshot
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa1104390openalex-snapshot
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa1105535openalex-snapshot
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa1611310openalex-snapshot
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa1810858openalex-snapshot
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
inferredcites →https://doi.org/10.1093/annonc/openalex-snapshot
ESMO Symposium on Immuno-Oncology 2015 Officers and Organisation
inferredcites →https://doi.org/10.1093/annonc/mdy174openalex-snapshot
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer
inferredcites →https://doi.org/10.1093/annonc/mdz394.053openalex-snapshot
Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
inferredcites →https://doi.org/10.1097/01.ogx.0000554460.78765.59openalex-snapshot
Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials
inferredcites →https://doi.org/10.1186/s13048-019-0484-6openalex-snapshot
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
inferredcites →https://doi.org/10.1200/jco.18.01568openalex-snapshot
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
inferredcites →https://doi.org/10.1200/jco.18.02238openalex-snapshot
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
inferredcites →https://doi.org/10.1200/jco.2013.54.6119openalex-snapshot
Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience
inferredcites →https://doi.org/10.1200/jco.2014.56.2728openalex-snapshot
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
inferredcites →https://doi.org/10.17615/hvp3-wg08openalex-snapshot
Integrated genomic analyses of ovarian carcinoma
inferredcites →https://doi.org/10.18632/oncotarget.7277openalex-snapshot
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
inferredcites →https://doi.org/10.3747/co.2007.148openalex-snapshot
Optimal Chemotherapy Treatment for Women with Recurrent Ovarian Cancer
inferredcites →https://doi.org/10.3802/jgo.2018.29.e31openalex-snapshot
Major clinical research advances in gynecologic cancer in 2017
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4786324openalex-extracted
Illuminating the Role of Curcumin for Breast Cancer Treatment with a New Leu/Val Mutation: An in Silico Study
inferred← citeshttps://doi.org/10.1002/ctm2.70078openalex-snapshot
Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer
inferred← citeshttps://doi.org/10.1002/slct.202504237openalex-snapshot
Multifaceted Elucidation of the BARD1‐Targeting Mechanism of Natural Ginsenosides Through Molecular Docking, Molecular Dynamics Simulations, DFT Calculations, and MM/PBSA Analyses
inferred← citeshttps://doi.org/10.1007/s40005-024-00705-7openalex-snapshot
A combination formulation of TPGS micelles loaded with paclitaxel and olaparib and a pH-thermosensitive hydrogel for treating peritoneal metastasis and drug-resistant ovarian cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-95116-6.00006-2openalex-snapshot
Pharmacogenomics and oncology: A therapeutic approach for cancer treatment
inferred← citeshttps://doi.org/10.1016/j.biopha.2022.113669openalex-snapshot
PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine
inferred← citeshttps://doi.org/10.1016/j.jddst.2023.104767openalex-snapshot
Poly vinyl pyrrolidone (PVP) based inhaled delivery carriers for olaparib for non-small cell lung cancer (NSCLC) treatment
inferred← citeshttps://doi.org/10.1016/j.ygeno.2024.110834openalex-snapshot
Boosting edgeR (Robust) by dealing with missing observations and gene-specific outliers in RNA-Seq profiles and its application to explore biomarker genes for diagnosis and therapies of ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.ygyno.2021.06.009openalex-snapshot
Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study
inferred← citeshttps://doi.org/10.1016/j.ygyno.2025.04.586openalex-snapshot
Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors
inferred← citeshttps://doi.org/10.1038/s41419-023-05963-1openalex-snapshot
Bcl-2 family inhibitors sensitize human cancer models to therapy
inferred← citeshttps://doi.org/10.1055/s-0041-1740323openalex-snapshot
Ayurveda Maintenance Therapy in Recurrent Ovarian Cancer
inferred← citeshttps://doi.org/10.1080/10543406.2022.2154940openalex-snapshot
Parameter estimation of Weibull distribution for the number of days between drug administration and early onset adverse event
inferred← citeshttps://doi.org/10.1080/14740338.2022.2047176openalex-snapshot
An update on the safety of olaparib for treating ovarian cancer
inferred← citeshttps://doi.org/10.1101/2021.07.30.454548openalex-snapshot
Early loss of endogenous NAD + following rotenone treatment leads to Sarm1 activation that is ameliorated by PARP inhibition
inferred← citeshttps://doi.org/10.1111/febs.16652openalex-snapshot
Early loss of endogenous NAD + following rotenone treatment leads to mitochondrial dysfunction and Sarm1 induction that is ameliorated by PARP inhibition
inferred← citeshttps://doi.org/10.1111/sji.13426openalex-snapshot
Production of novel peptide‐targeting antibodies for anti‐Müllerian hormone receptor 2 and induction of cytotoxicity in ovarian cancer cells
inferred← citeshttps://doi.org/10.1136/jim-2020-001602openalex-snapshot
Knockdown of Bag3 Synergizes with Olaparib to Kill Ovarian Cancer Cells via Repressing Autophagy
inferred← citeshttps://doi.org/10.1159/000533810openalex-snapshot
Next-Generation Sequencing of Breast Cancer in the Neoadjuvant Setting
inferred← citeshttps://doi.org/10.18632/oncotarget.27585openalex-snapshot
Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II
inferred← citeshttps://doi.org/10.21141/pjp.2023.05openalex-snapshot
Prevalence of Somatic BRCA1 and BRCA2 Mutations in Ovarian Cancer among Filipinos using Next Generation Sequencing
inferred← citeshttps://doi.org/10.2147/imcrj.s491062openalex-snapshot
Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case Report
inferred← citeshttps://doi.org/10.2174/0109298673331849240930140120openalex-snapshot
A Promising Druggable Target for Translational Therapy of Ovarian Cancer: A Molecular Profiling of Therapeutic Innovations, Extracellular Vesicle Acquired Resistance, and Signaling Pathways
inferred← citeshttps://doi.org/10.21873/anticanres.14530openalex-snapshot
Successful Management of Platinum-resistant Ovarian Cancer by Weekly Nedaplatin Followed by Olaparib: Three Case Reports
inferred← citeshttps://doi.org/10.21873/anticanres.16231openalex-snapshot
Analysis of Clinical Factors in Olaparib-related Anemia Using Adverse Drug Event Reporting Databases
inferred← citeshttps://doi.org/10.3389/fmolb.2022.903065openalex-snapshot
Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
inferred← citeshttps://doi.org/10.3389/fonc.2024.1514120openalex-snapshot
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments
inferred← citeshttps://doi.org/10.3390/cancers12113467openalex-snapshot
Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
inferred← citeshttps://doi.org/10.3390/cancers13215480openalex-snapshot
Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
inferred← citeshttps://doi.org/10.3390/cancers14153790openalex-snapshot
Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients
inferred← citeshttps://doi.org/10.3390/ijms21249715openalex-snapshot
PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality—An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness
inferred← citeshttps://doi.org/10.3390/ijms25158304openalex-snapshot
Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer
inferred← citeshttps://doi.org/10.4018/979-8-3693-3836-0.ch009openalex-snapshot
A Mechanistic Approach on the Regulation of Mitophagy Signaling in Cancer Drug Resistance
inferred← citeshttps://doi.org/10.7774/cevr.2022.11.2.163openalex-snapshot
Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.